Quick answers
- What is Carbidopa used for?
- The FDA-approved label (Lodosyn, Bausch Health US, LLC, July 1, 2020) says: “LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Carbidopa have a boxed warning?
- No. None of the 9 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Carbidopa?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Carbidopa been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Carbidopa?
- 9 companies list prescription products of Carbidopa in the FDA NDC Directory, including Aurobindo Pharma Limited, NorthStar Rx LLC and Oceanside Pharmaceuticals.
What Carbidopa is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. …
— FDA label: Lodosyn, Bausch Health US, LLC, effective July 1, 2020. Read the full label on DailyMed →
The FDA has 9 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 9 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 9 in the FDA NDC Directory |
| Brand names | Lodosyn |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| carbidopa 25 mg tablet | Generic | $0.5910 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Aurobindo Pharma Limited1 product
- NorthStar Rx LLC1 product
- Oceanside Pharmaceuticals1 product
- Bausch Health US, LLC1 product
- Edenbridge Pharmaceuticals LLC.1 product
- Lupin Pharmaceuticals, Inc.1 product
- Novel Laboratories, Inc.1 product
- Zydus Pharmaceuticals USA Inc.1 product
- Zydus Lifesciences Limited1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA017830 LODOSYN | Aton | April 25, 1977 | 23, latest February 21, 2014 2014: Labeling · 2014: Labeling · 2014: Labeling |
Generic approvals (4)
- ANDA205304Edenbridge Pharms · February 17, 2016
- ANDA204763Novel Labs Inc · October 20, 2017
- ANDA209910Zydus Pharms · May 7, 2018
- ANDA211055Aurobindo Pharma · October 21, 2019
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 260260, 261330 |
|---|---|
| SPL set ID of the quoted label | ff8e105b-7415-42d4-bbb2-b36cfb8945a5 |
| FDA labels (SPL) | 9 |
| FDA applications | NDA017830, 4 ANDA |
| Active ingredients (FDA) | CARBIDOPA |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Lodosyn, Bausch Health US, LLC, effective July 1, 2020; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →